EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging
Faubion WA, Fletcher JG, O'Byrne S, Feagan BG, de Villiers WJ, Salzberg B, Plevy S, Proctor DD, Valentine JF, Higgins PD, Harris JM, Diehl L, Wright L, Tew GW, Luca D, Basu K, Keir ME. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. The American Journal Of Gastroenterology 2013, 108: 1891. PMID: 24126633, DOI: 10.1038/ajg.2013.354.Peer-Reviewed Original ResearchConceptsComputed tomography enterographySerum IL-22Disease activityFecal calprotectinCrohn's diseaseSerum MMP9Ulcerative colitisCross-sectional imagingCD patientsIL-22Serum matrix metalloproteinase-9Bowel wall inflammationInflammatory disease activitySerum interleukin‐22Inflammatory bowel diseaseFindings of inflammationCrohn's disease activityMatrix metalloproteinase-9Endoscopy subscoreTomography enterographyUC patientsEndoscopy scoresBowel diseaseClinical symptomsWall inflammation